These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 20297862)

  • 21. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?
    Meyer-Massetti C; Cheng CM; Sharpe BA; Meier CR; Guglielmo BJ
    J Hosp Med; 2010 Apr; 5(4):E8-16. PubMed ID: 20394022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Torsade de Pointes/QT Prolongation Associated with Antifungal Triazoles: A Pharmacovigilance Study Based on the U.S. FDA Adverse Event Reporting System（FAERS）.
    Yu Z; Liao X
    J Pharm Pharm Sci; 2022; 25():237-243. PubMed ID: 35790147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimicrobial agents-associated with QT interval prolongation.
    Bril F; Gonzalez CD; Di Girolamo G
    Curr Drug Saf; 2010 Jan; 5(1):85-92. PubMed ID: 20210724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse event detection using the FDA post-marketing drug safety surveillance system: Cardiotoxicity associated with loperamide abuse and misuse.
    Swank KA; Wu E; Kortepeter C; McAninch J; Levin RL
    J Am Pharm Assoc (2003); 2017; 57(2S):S63-S67. PubMed ID: 28073687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.
    Poluzzi E; Raschi E; Koci A; Moretti U; Spina E; Behr ER; Sturkenboom M; De Ponti F
    Drug Saf; 2013 Jun; 36(6):467-79. PubMed ID: 23553446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Moxifloxacin-induced torsades de pointes.
    Sherazi S; DiSalle M; Daubert JP; Shah AH
    Cardiol J; 2008; 15(1):71-3. PubMed ID: 18651388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.
    Guns PJ; Johnson DM; Weltens E; Lissens J
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):125-34. PubMed ID: 22516473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.
    Saint-Gerons DM; Tabarés-Seisdedos R
    Eur J Clin Pharmacol; 2021 Oct; 77(10):1513-1521. PubMed ID: 33938974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval.
    Lorberbaum T; Sampson KJ; Woosley RL; Kass RS; Tatonetti NP
    Drug Saf; 2016 May; 39(5):433-41. PubMed ID: 26860921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cases of drug-induced Torsade de Pointes: a review of Belgian cases in the EudraVigilance database.
    Vandael E; Vandenberk B; Vandenberghe J; Willems R; Foulon V
    Acta Clin Belg; 2017 Dec; 72(6):385-390. PubMed ID: 28335691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study.
    Khan Q; Ismail M; Khan S
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):75. PubMed ID: 29191244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.
    Sarganas G; Garbe E; Klimpel A; Hering RC; Bronder E; Haverkamp W
    Europace; 2014 Jan; 16(1):101-8. PubMed ID: 23833046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.
    Wysowski DK; Corken A; Gallo-Torres H; Talarico L; Rodriguez EM
    Am J Gastroenterol; 2001 Jun; 96(6):1698-703. PubMed ID: 11419817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An experimental investigation of masking in the US FDA adverse event reporting system database.
    Wang HW; Hochberg AM; Pearson RK; Hauben M
    Drug Saf; 2010 Dec; 33(12):1117-33. PubMed ID: 21077702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proarrhythmic potential of antimicrobial agents.
    Simkó J; Csilek A; Karászi J; Lorincz I
    Infection; 2008 Jun; 36(3):194-206. PubMed ID: 18454341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation.
    Niedrig D; Maechler S; Hoppe L; Corti N; Kovari H; Russmann S
    Eur J Clin Pharmacol; 2016 Jul; 72(7):859-67. PubMed ID: 27023463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Torsade de Pointes and QT Prolongation With Antifungal Triazoles: Analysis Using a Pharmacovigilance Database.
    Ohyama K; Akiyama S; Iida M; Hori Y
    In Vivo; 2023; 37(6):2719-2725. PubMed ID: 37905641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.
    Briasoulis A; Agarwal V; Pierce WJ
    Cardiology; 2011; 120(2):103-10. PubMed ID: 22156660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors.
    Bertino JS; Owens RC; Carnes TD; Iannini PB
    Clin Infect Dis; 2002 Mar; 34(6):861-3. PubMed ID: 11830802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.